electronic-data-capture
(7)
Castor
Castor is a health-technology company that builds a cloud-based eClinical platform for running clinical trials - from electronic data capture (EDC) and eConsent to eCOA/ePRO and real-world evidence. Founded in 2012 in Amsterdam by physician-researcher Dr. Derk Arts, Castor set out to replace clunky, expensive trial software with a self-service, researcher-friendly system. Today it supports more than 15,000 studies across 90+ countries and is used by leading CROs and biopharma companies, while pushing decentralized trials and practical AI (Castor Catalyst, built with Google Cloud) into mainstream research.
IgniteData
IgniteData is a healthtech company automating the transfer of clinical trial data between hospital electronic health records (EHRs) and sponsors' electronic data capture (EDC) systems. Its flagship platform, Archer, is a cloud-based, system-agnostic 'Virtual Research Assistant' that uses HL7 FHIR and SMART on FHIR APIs to move clinically validated data securely and automatically, cutting manual transcription, reducing source data verification, and helping treatments reach patients faster. Founded in the UK and now operating on both sides of the Atlantic, IgniteData works with pharmaceutical sponsors like AstraZeneca and research hospitals including UCLH, Cambridge University Hospitals, and Memorial Sloan Kettering Cancer Center.
Derk Arts
Derk Arts is a Dutch physician-turned-entrepreneur and the founder and CEO of Castor, a clinical-trial software company he started in 2012 after coding the first version of its Electronic Data Capture platform himself. Trained as a medical doctor and epidemiologist with a PhD, he built Castor to make clinical research more inclusive, patient-centric, and data-driven. The platform now supports thousands of trials across roughly 90 countries and was used by the World Health Organization for its Solidarity Trial. Castor has raised more than $60 million, including a $45 million Series B in 2021, and Arts is a recognized voice on decentralized trials, eConsent, and the responsible use of AI in research.
ClinCapture
ClinCapture is an eClinical software company that builds cloud-based tools for running clinical trials - electronic data capture (EDC), ePRO/eCOA, eConsent, randomization, medical coding, and trial master file management. Born from consulting firm Clinovo and once known as the only free, fully validated open-source EDC in the world, it now markets a unified, AI-augmented platform called Captivate that lets sponsors and CROs design, launch, and manage studies from a single validated cloud system.
Scott Weidley
Scott Weidley is President, CEO and Chief Engineer of ClinCapture, the Las Vegas eClinical company that built its reputation on giving away validated electronic data capture software for free. With two decades in cloud and clinical software, Weidley has steered ClinCapture's Captivate platform toward AI baked into the structural layer of trial design, championed a low-and-no-cost access program called Weidley's Wish, and reinvented himself as a podcaster whose show 'Vibe with Scott Weidley' broadcasts from Vegas and has crossed three million YouTube views.
Medidata Solutions
Medidata Solutions is a New York-based, cloud software company that runs the digital plumbing of modern clinical research. Its flagship Rave EDC pioneered electronic data capture in clinical trials, and today its unified platform spans data capture, patient engagement, AI analytics, imaging, and trial operations. A Dassault Systèmes company since 2019, Medidata powers trials for most of the world's largest pharmaceutical companies and has supported the development of a large share of newly approved drugs and medical devices.
Mike Novotny
Mike Novotny is the founder and CEO of Medrio, a San Francisco-based eClinical SaaS company he started in his apartment in 2005. Over 15 years he bootstrapped Medrio into a nine-figure company that has helped customers win regulatory approvals for more than 100 treatments. After a sabbatical researching organizational development, he returned as CEO in 2025, betting that AI will reshape clinical trial data management. Before Medrio, he was CEO of Telosa, President of Ninaza, a UN research associate, and managed the fraud database at Visa. He holds degrees from Stanford, PUC Chile, and Columbia.